As a decoy receptor for IL-33, sST2 competitively binds to IL-33, thereby interfering with the IL-33/ST2L signaling pathway and modulating pathological processes such as atherosclerosis and cardiac remodeling (4). Here, IL33 is linked to atherosclerosis.